FDA Mandatory GRAS Notification Proposed Rule 2026: What Companies Need to Know

The FDA has proposed ending the ability to rely on a GRAS determination without notifying FDA. Under the proposed rule Substances Generally Recognized as Safe (docket FDA-2025-N-3262, RIN 0910-AJ02), published 11 August 2026, any company introducing a GRAS food substance into US commerce would have to notify the FDA. Comments are due 9 December 2026. It is a proposal, not yet law.

This is the most significant change to the GRAS framework since Congress created the exemption in 1958. The commercially important point is what the rule does not do: it does not abolish a company’s right to conclude that a substance is generally recognised as safe. It removes the ability to keep that conclusion private. Every qualifying GRAS conclusion would have to be filed with the FDA before the substance enters interstate commerce, converting a voluntary notification programme into a mandatory one.

Instrument	Applies from	Who is bound	Action required
Proposed rule “Substances Generally Recognized as Safe”, docket FDA-2025-N-3262, RIN 0910-AJ02, published 11 August 2026 (as at 14 August 2026, proposed)	Effective date to be set in the final rule; comment period closes 9 December 2026	Manufacturers introducing GRAS substances into US interstate commerce; domestic and foreign ingredient suppliers; food-contact substance makers; animal food producers	Inventory self-GRAS conclusions now; file comments by 9 December 2026; prepare to notify the FDA, or use the time-limited streamlined path for legacy substances

What is the FDA actually proposing to change?

Under the current framework, a company may conclude on its own that a food substance is generally recognised as safe and may market it without ever telling the FDA. Notifying the agency through the GRAS notice programme is optional. The FDA reports that more than 1,200 GRAS notices have been filed voluntarily since the programme opened in 1998, with 670 of those since January 2016, but the agency estimates roughly 1,000 further substances entered the food supply on self-determined GRAS conclusions that were never submitted.

The proposed rule would require the submission of a GRAS notice for the use of any human or animal food substance purported to be GRAS. In the FDA’s words, a person introducing such a substance into interstate commerce “must notify FDA of the basis for their conclusion” unless a specific exception applies. The scientific standard for GRAS status is not being rewritten; the change is procedural and transparency-driven. What was optional becomes compulsory.

Who must comply with the mandatory GRAS notification rule?

The obligation reaches everyone who relies on a GRAS conclusion to place a substance in the US food or animal food supply. That includes finished-product manufacturers, domestic and foreign ingredient suppliers, and makers of food-contact substances such as packaging. Foreign suppliers are squarely in scope: of the GRAS notices filed to date, 617 came from firms outside the United States, and 503 originated in countries where English is not the primary language. A supplier that has historically self-affirmed GRAS status and sold into the US without notifying the FDA would, once the rule is final, need to file.

Dietary supplement companies should read the boundary carefully. GRAS is a food-substance concept; a dietary ingredient that is new to the market is governed by the separate New Dietary Ingredient notification route under the Dietary Supplement Health and Education Act of 1994, not by GRAS. The overlap matters where a botanical, nutrient or novel ingredient is used both as a conventional food substance and in supplements, in that case the food use would fall within the proposed notification duty.

When does the rule take effect, and when are comments due?

The rule is a proposal as at 14 August 2026. Nothing is legally required yet. The FDA has set a comment deadline of 9 December 2026, and the operative effective and compliance dates will be fixed only when a final rule is issued. Companies should treat the comment window as the immediate deadline and the eventual effective date as the compliance horizon to plan against.

What is the time-limited streamlined submission path?

The FDA has built a temporary on-ramp for substances already in interstate commerce. During a time-limited window running up to the effective date of the final rule, firms could submit simplified information for legacy substances instead of preparing a full GRAS notice for each one. This is effectively a one-time reconciliation window: a chance to bring historically self-affirmed ingredients onto the FDA’s inventory at lower cost before the full notification requirement bites. The exact duration of the window will be confirmed in the final rule, so the streamlined route is best treated as time-sensitive rather than open-ended.

What will it cost?

The FDA estimates the present value of compliance costs over ten years at 89.6 million dollars at a 3 percent discount rate, with a range of 34.9 million to 210.0 million dollars, equivalent to roughly 10.5 million dollars annually. The heaviest burden falls on suppliers with large portfolios of self-determined ingredients that have never been notified, because each use will ultimately need a filing.

Recommended actions

• Compile a GRAS inventory now. The regulatory affairs lead should list every substance and use the company relies on a self-determined GRAS conclusion for, flagging which have never been notified to the FDA. This is the workload the rule converts into filings.
• File a comment by 9 December 2026. Any manufacturer or supplier materially affected, particularly foreign suppliers and food-contact makers — should submit evidence on cost and feasibility to docket FDA-2025-N-3262 while the record is open.
• Model the streamlined window. Identify legacy substances that would qualify for the simplified submission path and prepare the underlying safety dossiers so they can be filed quickly once the window opens.
• Brief procurement and overseas suppliers. Importers should tell foreign ingredient suppliers that self-affirmation without an FDA filing will not survive the final rule, and build notification status into supplier qualification.
• Separate the supplement question. Confirm whether any ingredient is regulated as a food substance, a New Dietary Ingredient, or both, so the correct notification route is used.

CosmeReg supports food businesses with FDA food facility registration, US Agent representation and compliance strategy, and can help map a company’s self-determined GRAS portfolio against the proposed notification duty before the comment window closes.

Frequently asked questions

Does the proposed rule ban self-determined GRAS conclusions?

No. A company may still reach its own scientific conclusion that a substance is generally recognised as safe. What changes is that the conclusion must be notified to the FDA before the substance enters interstate commerce, rather than kept internal. The rule ends private self-affirmation, not the GRAS pathway itself. As at 14 August 2026 this remains a proposal.

When would companies have to comply?

There is no compliance date yet. The rule was published on 11 August 2026 as a proposal, with comments due by 9 December 2026. Mandatory notification would begin only from the effective date set in a future final rule. Companies should use the interval to inventory their GRAS conclusions and prepare filings rather than wait for the final text.

How does this affect foreign ingredient suppliers?

Foreign suppliers relying on self-determined GRAS status to sell into the United States would need to file GRAS notices once the rule is final. Foreign firms already account for 617 of the notices filed to date. Overseas suppliers should begin assembling the safety basis for each GRAS use now, because notification, not self-affirmation, would become a condition for relying on GRAS status for U.S. market access if the rule is finalized substantially as proposed.

What is the streamlined submission path and who should use it?

It is a time-limited option letting firms submit simplified information for substances already in commerce before the final rule takes effect, instead of a full GRAS notice for each. Companies with large legacy portfolios of never-notified ingredients benefit most, because it lowers the cost of regularising historic self-affirmations. The window’s exact length will be set in the final rule.

Does this rule apply to dietary supplements?

Only at the overlap. GRAS governs food substances, while new dietary ingredients follow the separate NDI notification route under DSHEA 1994. A substance used both as a conventional food ingredient and in supplements would fall within the proposed GRAS notification duty for its food use. Supplement-only ingredients remain governed by the NDI and DSHEA framework.